Lilly plans to steer GLP-1 profits into women's health, report says

Eli Lilly plans to direct profits from its GLP-1 weight-loss and diabetes medicines into a broader push into women's health, Bloomberg reported on Sept. 10, 2026 ^[1]. The company has been assembling experts and looking for new medicines in areas that include bone health and endometriosis, according to people familiar with the matter ^[1]. The report was carried under the headline "Eli Lilly plans bigger push into women's health using GLP-1 drug windfall" ^[2].

Bloomberg described the effort as one of the "unconventional steps" the company — which it calls the world's largest pharmaceutical company — is taking with the windfall from its weight-loss and diabetes shots to find and fund its next act ^[1]. The article was published the morning of Sept. 10 and updated that afternoon ^[1].

What the report does not include is nearly as notable as what it does. There are no named drugs, no dollar amounts, no trial starts and no dates ^[1]. Lilly has not published specific targets or a timeline for the effort, and the company has not confirmed the plans described by Bloomberg's anonymous sources ^[1]. The report does not say how far along any women's health program is, whether any candidate medicine has entered human testing, or whether the effort involves GLP-1 drugs at all ^[1].

The money behind the plan comes from Lilly's weight-loss and diabetes shots ^[1], a franchise that includes tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for obesity. Bloomberg frames the women's health move as part of a pattern in which revenue from that franchise pays for work outside obesity and diabetes, though the article does not list the size of the investment or the number of people involved ^[1].

Why it matters for patients

For people taking Mounjaro or Zepbound today, the report describes no change to those medicines. No supply, labeling, price or insurance-coverage change was announced ^[1]. Where a company spends its profits is a separate question from what its approved products do and who can get them, and the report does not address pricing, coverage or supply at all ^[1].

The two areas named — bone health and endometriosis — cover a wide range of conditions, and the report gives no detail on which specific conditions within those areas Lilly is targeting or what kind of treatments it is looking for ^[1]. Because the effort is described as assembling experts and hunting for medicines, it appears to be at an early stage ^[1]. Any medicine that comes out of it would have to go through clinical trials and regulatory review before reaching patients, so this is not a near-term change for anyone's treatment options ^[1].

It is also not known whether new women's health treatments would be combined with, or marketed alongside, Lilly's existing obesity and diabetes drugs. That question has not been answered in the report ^[1].

What happens next

No milestones or dates have been announced ^[1]. Lilly has not disclosed which programs it intends to fund, how much it plans to spend, or when it expects results ^[1]. Because the account is based on people familiar with the matter rather than company statements, the scope and timing of the push remain unconfirmed ^[1]. The next verifiable signals would come from Lilly's own announcements or financial disclosures; none specific to a women's health push have been reported ^[1].